CAJ | 학술논문

成纤维生长因子受体1(fibroblast growth factor receptor 1,FGFR1)是受体酪氨酸激酶家族的成员.近期研究显示在20％的肺鳞癌患者中发现FGFR1扩增,而肺腺癌中却很少,并且有实验明确其与吸烟剂量显著相关.在体内试验中利用FGFR1抑制剂阻断FGFR1通路导致肿瘤显著缩小,提示FGFR1抑制剂可能成为肺鳞癌中FGFR1扩增患者有效的治疗选择.同时FGFR1抑制物正在临床试验第一阶段的测试中.FGFR1扩增有望成为肺鳞癌的治疗靶点.本文从成纤维生长因子/FGFRs信号通路生物学特性、肿癌中FGFRs、FGFR1扩增在肺癌中的表达和其靶向药物研究进展以及与临床关系等几个方面予以综述.
성섬유생장인자수체1(fibroblast growth factor receptor 1,FGFR1)시수체락안산격매가족적성원.근기연구현시재20％적폐린암환자중발현FGFR1확증,이폐선암중각흔소,병차유실험명학기여흡연제량현저상관.재체내시험중이용FGFR1억제제조단FGFR1통로도치종류현저축소,제시FGFR1억제제가능성위폐린암중FGFR1확증환자유효적치료선택.동시FGFR1억제물정재림상시험제일계단적측시중.FGFR1확증유망성위폐린암적치료파점.본문종성섬유생장인자/FGFRs신호통로생물학특성、종암중FGFRs、FGFR1확증재폐암중적표체화기파향약물연구진전이급여림상관계등궤개방면여이종술.
Fibroblast growth factor receptor 1 (FGFR1) is a member of receptor tyrosine kinase family.Recently,FGFR1 amplification has been found in 20％ of patients with squamous cell carcinoma of the lung and rarely in lung adenocarcinoma,and experiments reveal that it has direct association with the smoking dosage significantly.In vivo studies have demonstrated inhibition of the FGFR1 pathway with FGFR1 inhibitors lead to significant shrinkage of tumor,suggesting that FGFR1 inhibitors might be an effective therapeutic option in squamous cell carcinoma of lung with FGFR1 amplification.And FGFR1 tyrosine kinase inhibitors are currently in early phase clinical testing.FGFR1 represents a potential therapeutic target in squamous cell carcinoma of lung.This review focuses on biological characteristics of FGFs/FGFRs signal pathways,FGFRs in tumor,the expression of FGFR1 amplification in lung cancer and progress of targeted drugs as well as relationship of it with clinic.